Part of our Foundation Fundlist WORLDWIDE HEALTHCARE TRUST ORD GBP0.025

Symbol: WWH

Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Past Performance

  • 24th Apr 2019 to 24th Apr 202027.42%
  • 24th Apr 2020 to 24th Apr 202117.76%
  • 24th Apr 2021 to 24th Apr 2022-15.65%
  • 24th Apr 2022 to 24th Apr 20232.12%
  • 24th Apr 2023 to 24th Apr 20243.46%

Key Information

Benchmark MSCI World/Health Care
Sector IT Biotechnology & Healthcare
Gearing 107%
Ex-Dividend Date 23 Nov 2023
Dividend Pay Date 11 Jan 2024
Total Dividends - Year to Date3.1
Dividend Yield (%)0.9295

Net Asset Value (Nav)

Latest actual NAV 371.11
Latest actual NAV date 22/04/2024
NAV frequency Daily
Premium/Discount -10.13%

Part of our Foundation Fundlist Part of our Foundation Fundlist
WHY IS THIS FUND ON OUR FOUNDATION FUNDLIST?

Charges

Total Ongoing Charges 
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing.
1.2888%
Performance Fee No
AMC 0.80%
Our Platform Charge
We charge a platform fee of 0.35% per annum on the value of all stocks & shares held across all accounts, minimum £24 and maximum £240 per annum, charged pro-rata monthly in arrears. A full list of our rates and charges can be found here .
0.35%

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here
0.35%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
1.2888%
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Company

Business Summary

Worldwide Healthcare Trust PLC is a specialist investment trust. The Company invests in the global healthcare sector with the objective of achieving a high level of capital growth. It invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It invests up to 10% of the portfolio, at the time of acquisition, in unquoted securities. It invests approximately 50% of the portfolio in larger companies, and at over 20% of the portfolio in smaller companies. It may invest over 5% of the portfolio, at the time of acquisition, in debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies. It may invest over 30% of the portfolio in companies under sectors, such as healthcare equipment and supplies, and healthcare providers and services. Its alternative investment fund manager is Frostrow Capital LLP. OrbiMed Capital LLC is its portfolio manager.

Financial Summary

BRIEF: For the six months ended 30 September 2023, Worldwide Healthcare Trust PLC revenues decreased from £76.9M to -£5.4M. Net loss totaled £20.7M vs. income of £65.9M. Revenues reflect Losses)/Gains on investments) decrease from £82.7M to -£11.1M. Net loss reflects Other expenses increase of 14% to £686K (expense). Dividend per share remained flat at £0.01.

Performance

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Cumulative Performance

      1 month3 months6 months1 year3 years5 years
      1.52% 6.89% 13.13% 3.46% -10.88% 33.73%

      Important Information
      Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.

      The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.

      Composition

      Important Documents


      The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.

      Fund Provider Factsheet
      The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured. &nbsp;
      FUND PROVIDER FACTSHEET
      251,511 bytes PDF Document; last updated 29 Feb 2024
      Key Information Document This document, issued by the product provider, provides key information about an investment product. The information is required by law to help potential investors understand the nature, risks, costs, potential gains and losses of the product and enable comparison with other products.
      KEY INFORMATION DOCUMENT
      279,662 bytes PDF Document; last updated 05 Apr 2024
      Annual Report A report published by the Fund Management Group detailing the progress of the fund during the course of the previous 12 months. The information provided includes a financial statement for the group as a whole.
      ANNUAL REPORT
      4,731,356 bytes PDF Document; last updated 31 Mar 2023
      Semi Annual Report Published periodically through the course of the financial year of the fund, the report provides an overview of the fund's performance and the prospects for the remainder of the year. Included are portfolio changes (i.e. which stocks have been bought and sold), and changes in the geographical breakdown during the course of the previous 12 months.
      SEMI-ANNUAL REPORT
      21,792,805 bytes PDF Document; last updated 30 Sep 2023

      Management Team

      Sven H Borho Trevor Polischuk

      Sven H Borho has managed this fund for 29 years .

      Sven H Borho Sven H. Borho CFA, is a founding Partner of OrbiMed. Mr. Borho is a senior member of the public equity team and he is a portfolio manager for OrbiMed's public equity and hedge funds. Mr. Borho has played an integral role in the growth of OrbiMed's asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. Mr. Borho studied business administration at Bayreuth University in Germany and received an M.Sc. (Econ.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Trevor Polischuk has managed this fund for 6 years and 4 months.

      Trevor Polischuk Trevor M. Polischuk, Ph.D., is a Public Equity Partner focused on the global pharmaceutical industry. Previously, he worked at Lehman Brothers as a Senior Research Analyst covering the U.S. pharmaceutical industry. Dr. Polischuk began his career at Warner Lambert as a member of the Pharmaceutical Global Marketing Planning team. In this role, he coordinated marketing activities for the second generation gabapentinoid product, Pregabalin. Dr. Polischuk holds a Doctorate in Neuropharmacology & Gross Human Anatomy from Queen's University and an M.B.A. from Queen's University.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/03/2023

      31/03/2022

      31/03/2021

      31/03/2020

      31/03/2019

      31/03/2018

      Total Revenue 16.03 -135.35 530.44 108.00 176.96 50.85
      Gross profit -5.69 -136.49 480.51 93.51 168.52 29.25
      Operating Profit/Loss -6.53 -137.86 479.73 92.90 167.96 28.71
      Profit Before Tax -6.52 -137.86 479.73 92.90 167.96 28.71
      Profit After Tax -8.79 -141.53 477.02 90.78 166.24 27.18
      Equity Holders of Parent Company -8.79 -141.53 477.02 90.78 166.24 27.18
      Minority Interest NIL NIL NIL NIL NIL NIL


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/03/2023

      31/03/2022

      31/03/2021

      31/03/2020

      31/03/2019

      31/03/2018

      Total Non-Current Assets 2,186.63 2,380.13 2,434.90 1,684.58 1,390.58 1,294.03
      Total Current Assets 63.30 41.32 47.77 18.44 63.26 17.12
      Total Assets 2,249.93 2,421.45 2,482.67 1,703.02 1,453.84 1,311.15
      Total Liabilities 99.21 153.22 101.24 164.73 21.74 108.96
      Total Net Assets 2,150.72 2,268.23 2,381.43 1,538.30 1,432.09 1,202.19
      Shareholders Funds 2,150.72 2,268.23 2,381.43 1,538.30 1,432.09 1,202.19
      Minority Interests NIL NIL NIL NIL NIL NIL
      Total Equity 2,150.72 2,268.23 2,381.43 1,538.30 1,432.09 1,202.19

      Investment involves risk. You may get back less than invested.